BioCentury
ARTICLE | Strategy

SHP building business

June 25, 2007 7:00 AM UTC

Shire plc already has had a busy year, with the $1.6 billion acquisition of New River Pharmaceuticals Inc., last week's entry into the new therapeutic area of regenerative medicine, and the approval of three new drugs: Vyvanse in the U.S. for pediatric attention deficit hyperactivity disorder, Lialda/Mezavant mesalamine for ulcerative colitis in the U.S. and Europe, and Elaprase idursulfase in Europe for Hunter syndrome.

Shire (LSE:SHP; SHPGY, Basingstoke, U.K.) also has been continuing its European rollout of both Fosrenol lanthanum carbonate for end-stage renal failure patients receiving dialysis in Europe, and Dynepo epoetin delta to treat anemia in patients with chronic renal failure...